{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:55:12Z","timestamp":1790952912713,"version":"4.1.0"},"reference-count":95,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    The gut microbiota is well established as a key modulator of systemic immunity, with growing evidence supporting its impact on lung cancer immunotherapy outcomes. However, the contributions of the lung microbiota and the recently recognized intratumoral microbiota remain less defined. This review synthesizes current evidence on the gut-lung axis, consolidating the tripartite regulatory network of gut, lung, and intratumoral microbiota in shaping the lung cancer immune microenvironment and immunotherapy response. We discuss how gut-derived metabolites such as indole-3-propionic acid may remotely modulate CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell stemness, how lung microbiota locally influence alveolar macrophage polarization through pattern recognition receptor signaling, and how intratumoral microbiota have been implicated in STING pathway activation, Treg\/M2 polarization, and PD-L1 expression. Although these microbial communities are conceptually linked through the lung-gut axis, the empirical evidence supporting their integrated network remains preliminary, and the clinical relevance of these interactions requires further investigation. Future research should focus on establishing causal relationships between specific microbial taxa and immunotherapy outcomes, elucidating spatial heterogeneity through multi-omics approaches, and validating microbiota-targeted interventions in well-designed prospective studies. This review offers a framework for critically evaluating the current evidence and identifying key knowledge gaps in this evolving field.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1907688","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:25:16Z","timestamp":1790951116000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Lung microbiota, gut microbiota, and the lung-gut axis in lung cancer immunotherapy: a tripartite regulatory perspective"],"prefix":"10.3389","volume":"17","author":[{"given":"Qin","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Respiratory and Critical Medicine, Tianjin Chest Hospital","place":["Tianjin, China"]},{"name":"Tianjin Key Laboratory of Cancer Prevention and Therapy, Department of Thoracic Oncology, Tianjin Cancer Institute & Hospital, Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Cancer Prevention and Therapy, Department of Thoracic Oncology, Tianjin Cancer Institute & Hospital, Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daqiang","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Tianjin Chest Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwen","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Medicine, Tianjin Chest Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115891","article-title":"Advances and challenges in the treatment of lung cancer","volume":"169","author":"Li","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1186\/s12885-025-15094-9","article-title":"Unraveling gut microbiome interferences in cancer immunotherapy: a meta-analysis of diverse drug effects","volume":"25","author":"Xu","year":"2025","journal-title":"BMC Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01061-7","article-title":"Treatment of NSCLC after chemoimmunotherapy \u2014 are we making headway","volume":"22","author":"Reck","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100773","article-title":"Microbiota-derived metabolites: key modulators of cancer immunotherapies","volume":"6","author":"Perl","year":"2025","journal-title":"Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-024-01124-2","article-title":"Tumour mutational burden and immune checkpoint inhibitor response in non-small cell lung cancer: a continuous modelling approach","volume":"20","author":"Sorich","year":"2025","journal-title":"Target Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1655780","article-title":"Lung cancer and the gut-microbiota-lung axis: emerging evidence and potential clinical implications","volume":"12","author":"Liu","year":"2025","journal-title":"Front Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.126977","article-title":"Gut-lung microbiota axis shapes the immune microenvironment and immunotherapeutic response in lung cancer","volume":"22","author":"Liu","year":"2026","journal-title":"Int J Biol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4110\/in.2026.26.e7","article-title":"Harnessing the gut microbiota to improve cancer immunotherapy: focus on lung cancer","volume":"26","author":"Park","year":"2026","journal-title":"Immune Netw"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03240-y","article-title":"Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab","volume":"30","author":"Alban","year":"2024","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41419-025-07471-w","article-title":"High baseline levels of PD-L1 reduce the heterogeneity of immune checkpoint signature and sensitize anti-PD1 therapy in lung and colorectal cancers","volume":"16","author":"Fan","year":"2025","journal-title":"Cell Death Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2025.06.012","article-title":"Advances and mechanisms of gut microbiota modulation in enhancing immune checkpoint inhibitor efficacy","volume":"114","author":"Chen","year":"2025","journal-title":"Semin Cancer Biol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms13112595","article-title":"Multi-kingdom gut microbiome interaction characteristics predict immune checkpoint inhibitor efficacy across pan-cancer cohorts","volume":"13","author":"Qiao","year":"2025","journal-title":"Microorganisms"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1676302","article-title":"Respiratory microbiome-host interaction on lung carcinogenesis, immunity, and immunotherapy","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40779-025-00623-1","article-title":"Advancements in understanding tumor-resident bacteria and their application in cancer therapy","volume":"12","author":"Luo","year":"2025","journal-title":"Mil Med Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27010255","article-title":"Intratumoral microbiota in lung cancer: emerging roles in TME modulation and immunotherapy response","volume":"27","author":"Yang","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1653727","article-title":"Intratumoral microbiota: synergistic reshaping of lung cancer microenvironment via inflammation and immunity","volume":"16","author":"Zhang","year":"2026","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217096","article-title":"Gut microbial metabolites in lung cancer development and immunotherapy: novel insights into gut-lung axis","volume":"598","author":"Li","year":"2024","journal-title":"Cancer Lett"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0324230","article-title":"The role of gut leakage and immune cell miss-homing on gut dysbiosis-induced lung inflammation in a DSS mice model","volume":"20","author":"Eladham","year":"2025","journal-title":"PloS One"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-022-00821-x","article-title":"The dynamic lung microbiome in health and disease","volume":"21","author":"Natalini","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.33","article-title":"The human lung microbiome\u2014a hidden link between microbes and human health and diseases","volume":"1","author":"Yi","year":"2022","journal-title":"iMeta"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201501-029OC","article-title":"Spatial variation in the healthy human lung microbiome and the adapted island model of lung biogeography","volume":"12","author":"Dickson","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"B22","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1146\/annurev-physiol-021115-105238","article-title":"The microbiome and the respiratory tract","volume":"78","author":"Dickson","year":"2016","journal-title":"Annu Rev Physiol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(14)70028-1","article-title":"Towards an ecology of the lung: new conceptual models of pulmonary microbiology and pneumonia pathogenesis","volume":"2","author":"Dickson","year":"2014","journal-title":"Lancet Respir Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1514872","article-title":"Carcinogenic and anticancer activities of microbiota-derived secondary bile acids","volume":"15","author":"Kouhzad","year":"2025","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4274\/ThoracResPract.2025.s009","article-title":"Effects of Staphylococcus aureus on lung cancer cells","volume":"26","author":"Ece","year":"2025","journal-title":"Thorac Res Pract"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201710-2118OC","article-title":"Airway microbiota is associated with upregulation of the PI3K pathway in lung cancer","volume":"198","author":"Tsay","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1038\/s41598-024-52296-w","article-title":"Prediction of lung cancer using novel biomarkers based on microbiome profiling of bronchoalveolar lavage fluid","volume":"14","author":"Kim","year":"2024","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00203-021-02516-y","article-title":"Structural diversity, functional aspects and future therapeutic applications of human gut microbiome","volume":"203","author":"Ghosh","year":"2021","journal-title":"Arch Microbiol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2025.1565609","article-title":"An overview of basic pathophysiological interactions between gut bacteria and their host","volume":"12","author":"Simonson","year":"2025","journal-title":"Front Nutr"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1626002","article-title":"Enhanced metagenomic strategies for elucidating the complexities of gut microbiota: a review","volume":"16","author":"Li","year":"2025","journal-title":"Front Microbiol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1604310","article-title":"T lymphocyte heterogeneity in NSCLC: implications for biomarker development and therapeutic innovation","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03642-6","article-title":"Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes","volume":"31","author":"Wu","year":"2025","journal-title":"Nat Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v31.i5.99913","article-title":"Unlocking the secrets of the human gut microbiota: comprehensive review on its role in different diseases","volume":"31","author":"Paul","year":"2025","journal-title":"World J Gastroenterol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn121430-20200603-00792","article-title":"Fei yu da chang xiang biao li\u201d zai ji wei zhong zheng zhong de xian dai jie du [Modern interpretation of \u201cthe lung and large intestine being interior-exteriorly related\u201d in critical illness","volume":"32","author":"Zhao","year":"2020","journal-title":"Chin J Crit Care Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1218565","article-title":"The lung-gut crosstalk in respiratory and inflammatory bowel disease","volume":"13","author":"Du","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.prrv.2006.04.192","article-title":"The lung and the gut: common origins, close links","volume":"7","author":"Girosi","year":"2006","journal-title":"Paediatr Respir Rev"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.10.066","article-title":"The microbiota-gut-brain axis: from motility to mood","volume":"160","author":"Margolis","year":"2021","journal-title":"Gastroenterology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1126\/science.aay9189","article-title":"The human tumor microbiome is composed of tumor type-specific intracellular bacteria","volume":"368","author":"Nejman","year":"2020","journal-title":"Science"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1515\/jtim-2024-0038","article-title":"Intratumoral microbiota in orchestrating cancer immunotherapy response","volume":"12","author":"Zou","year":"2025","journal-title":"J Transl Intern Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1614731","article-title":"Dissecting the intratumoral microbiome landscape in lung cancer","volume":"16","author":"Zhao","year":"2025","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41392-022-01304-4","article-title":"Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1675448","article-title":"Influence of stage-specific and location-related intratumoral microbiota on prognosis and metabolic reprogramming in non-small cell lung cancer","volume":"16","author":"Zhao","year":"2026","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02566-6","article-title":"Intratumoral microbiome: the double-edged sword in remodeling cancer immunotherapy","volume":"25","author":"Yan","year":"2026","journal-title":"Mol Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2026.109381","article-title":"Microbiota biomarkers as predictors on immunotherapy response in patients with advanced non-small cell lung cancer","volume":"216","author":"Vicente-Valor","year":"2026","journal-title":"Lung Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1603822","article-title":"Multi-omics analysis untangles the crosstalk between intratumor microbiome, lactic acid metabolism and immune status in lung squamous cell carcinoma","volume":"16","author":"Qiu","year":"2025","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1186\/s12866-025-04325-5","article-title":"Characteristics of gut and lung microbiota in patients with lung masses and their relationship with clinical features","volume":"25","author":"Yang","year":"2025","journal-title":"BMC Microbiol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202509604","article-title":"Intravenous iRGD-guided, RBC-membrane camouflaged Lactococcus lactis remodels cold NSCLC and enhances PD-1 blockade","volume":"12","author":"Chen","year":"2025","journal-title":"Adv Sci"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/j.ccell.2023.08.012","article-title":"The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell"},{"key":"B49","doi-asserted-by":"publisher","first-page":"6750","DOI":"10.1038\/s41598-024-57251-3","article-title":"Bile acid metabolites enhance expression of cathelicidin antimicrobial peptide in airway epithelium through activation of the TGR5-ERK1\/2 pathway","volume":"14","author":"Myszor","year":"2024","journal-title":"Sci Rep"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00039.2023","article-title":"Lung antimicrobial proteins and peptides: from host defense to therapeutic strategies","volume":"104","author":"Di","year":"2024","journal-title":"Physiol Rev"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13195","article-title":"Respiratory microbiome and epithelial interactions shape immunity in the lungs","volume":"160","author":"Invernizzi","year":"2020","journal-title":"Immunology"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2025.103192","article-title":"Chlorogenic acid-based combinations alleviate Streptococcus pneumoniae-induced injury in canine lung epithelium by targeting integrin-extracellular matrix interactions","volume":"98","author":"Bai","year":"2026","journal-title":"Tissue Cell"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S97071","article-title":"The effects of repeated Toll-like receptors 2 and 4 stimulation in COPD alveolar macrophages","volume":"13","author":"Lea","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-022-01196-8","article-title":"Multi-omics analyses of airway host-microbe interactions in chronic obstructive pulmonary disease identify potential therapeutic interventions","volume":"7","author":"Yan","year":"2022","journal-title":"Nat Microbiol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2024-0159OC","article-title":"Indole-3-acetic acid protects against lipopolysaccharide-induced endothelial cell dysfunction and lung injury through the activation of USP40","volume":"71","author":"Shaheen","year":"2024","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.seminoncol.2025.152398","article-title":"The effects of microbiota-derived short-chain fatty acids on T lymphocytes: from autoimmune diseases to cancer","volume":"52","author":"Saadh","year":"2025","journal-title":"Semin Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.08.090","article-title":"Modulation of pulmonary microbiota by antibiotic or probiotic aerosol therapy: a strategy to promote immunosurveillance against lung metastases","volume":"24","author":"Le Noci","year":"2018","journal-title":"Cell Rep"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-00987-1","article-title":"Complex regulatory effects of gut microbial short-chain fatty acids on immune tolerance and autoimmunity","volume":"20","author":"Kim","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115821","article-title":"Gut microbiome metabolites in lung cancer: the emerging importance of short-chain fatty acids","volume":"168","author":"Bishoyi","year":"2026","journal-title":"Int Immunopharmacol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.chom.2026.02.002","article-title":"Strain-level genetic heterogeneity and colonization dynamics drive microbiome therapeutic efficacy","volume":"34","author":"Chen","year":"2026","journal-title":"Cell Host Microbe"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/j.cell.2024.02.022","article-title":"Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer","volume":"187","author":"Jia","year":"2024","journal-title":"Cell"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1638352","article-title":"Interplay between bile acids, gut microbiota, and the tumor immune microenvironment: mechanistic insights and therapeutic strategies","volume":"16","author":"Tong","year":"2025","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.apsb.2021.07.011","article-title":"TGR5 deficiency activates antitumor immunity in non-small cell lung cancer via restraining M2 macrophage polarization","volume":"12","author":"Zhao","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.155699","article-title":"The dual role of 20(S)-protopanaxadiol in alleviating pulmonary fibrosis through the gut-lung axis","volume":"129","author":"Ruan","year":"2024","journal-title":"Phytomedicine"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27041905","article-title":"The dynamic gut microbiota: monitoring alterations during lung cancer progression for diagnosis and precision medicine","volume":"27","author":"Xiao","year":"2026","journal-title":"Int J Mol Sci"},{"key":"B66","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s00262-025-04275-x","article-title":"Commensal bacteria antigen-mediated immune response enhances anti-tumor immunity","volume":"75","author":"Lee","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2026.1890287","article-title":"Microbial metabolites and the gut-lung axis in non-small cell lung cancer immunotherapy: evidence boundaries and translational implications","volume":"13","author":"Zheng","year":"2026","journal-title":"Front Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"key":"B71","doi-asserted-by":"publisher","first-page":"6139","DOI":"10.1038\/s41598-025-89406-1","article-title":"Gut microbial predictors of first-line immunotherapy efficacy in advanced NSCLC patients","volume":"15","author":"Grenda","year":"2025","journal-title":"Sci Rep"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2026.106077","article-title":"Gut microbiome-driven modulation of the tumor immune microenvironment optimizes dual checkpoint blockade in advanced non-small-cell lung cancer","volume":"11","author":"Katayama","year":"2026","journal-title":"ESMO Open"},{"key":"B73","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/s12967-025-06370-0","article-title":"Prioritizing gut microbial SNPs linked to immunotherapy outcomes in NSCLC patients by integrative bioinformatics analysis","volume":"23","author":"Raziq","year":"2025","journal-title":"J Transl Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy103","article-title":"Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer","volume":"29","author":"Derosa","year":"2018","journal-title":"Ann Oncol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/CEJ.0000000000000912","article-title":"Effects of antibiotics on immunotherapy in patients with metastatic non-small cell lung cancer","volume":"34","author":"Hu","year":"2025","journal-title":"Eur J Cancer Prev"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1409","article-title":"1354P retrospective audit to determine the effect of antibiotic therapy on immune checkpoint inhibitor efficacy in stage IV NSCLC","volume":"35","author":"Parekh","year":"2024","journal-title":"Ann Oncol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1186\/s12964-024-01771-y","article-title":"IL-1\u03b2 mediates Candida tropicalis-induced immunosuppressive function of MDSCs to foster colorectal cancer","volume":"22","author":"Zhang","year":"2024","journal-title":"Cell Commun Signal"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.157915","article-title":"Bronchoalveolar lavage fluid reveals factors contributing to the efficacy of PD-1 blockade in lung cancer","volume":"7","author":"Masuhiro","year":"2022","journal-title":"JCI Insight"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-472902","article-title":"Gut microbiota in immuno-oncology: a practical guide for medical oncologists with a focus on antibiotics stewardship","volume":"45","author":"Elkrief","year":"2025","journal-title":"ASCO Educ Book"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3779\/j.issn.1009-3419.2025.101.21","article-title":"Fecal microbiota transplantation: a promising avenue for lung cancer therapy","volume":"28","author":"Hong","year":"2025","journal-title":"Chin J Lung Cancer"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","volume":"371","author":"Baruch","year":"2021","journal-title":"Science"},{"key":"B82","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","article-title":"Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients","volume":"371","author":"Davar","year":"2021","journal-title":"Science"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04186-5","article-title":"Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial","volume":"32","author":"Duttagupta","year":"2026","journal-title":"Nat Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1186\/s12967-026-07885-w","article-title":"Fecal microbiota transplantation for advanced non-small cell lung cancer with secondary PD-1 resistance: efficacy, prognostic factors and microbiome diversity analysis","volume":"24","author":"Huang","year":"2026","journal-title":"J Transl Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04189-2","article-title":"Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial","volume":"32","author":"Porcari","year":"2026","journal-title":"Nat Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2026.102972","article-title":"Clostridium butyricum and butyrate enhance PD-1 inhibitor therapy in non-small cell lung cancer by regulating the HDAC1\/ID2\/IL-12R pathway","volume":"72","author":"Chen","year":"2026","journal-title":"Transl Oncol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"13859","DOI":"10.1038\/s41598-026-44743-7","article-title":"Impact of microbiome-modulating strategies in cancer patients receiving immunotherapy (MSIT): a systematic review and meta-analysis","volume":"16","author":"Thu","year":"2026","journal-title":"Sci Rep"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1518474","article-title":"Gut microbes and immunotherapy for non-small cell lung cancer: a systematic review","volume":"15","author":"Jin","year":"2025","journal-title":"Front Oncol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"23398","DOI":"10.1038\/s41598-025-08049-4","article-title":"Characteristics of the gut microbiota in patients with advanced non-small cell lung cancer who responded to immune checkpoint inhibitors","volume":"15","author":"Komatsu","year":"2025","journal-title":"Sci Rep"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1750569","article-title":"A probiotic bacterium modulates antitumour \u03b3\u03b4 T-cell responses in lung cancer","volume":"17","author":"Goto","year":"2026","journal-title":"Front Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61091595","article-title":"Clinical evidence for microbiome-based strategies in cancer immunotherapy: a state-of-the-art review","volume":"61","author":"Petrelli","year":"2025","journal-title":"Medicina"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.7507\/1671-6205.202405072","article-title":"Kang sheng su bao lu dui wan qi fei ai mian yi zhi liao yu hou de ying xiang [Effect of antibiotic exposure on the prognosis of immunotherapy in advanced lung cancer","volume":"24","author":"Xie","year":"2025","journal-title":"Chin J Respir Crit Care Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1665239","article-title":"Pharmacological strategies to overcome immune checkpoint inhibitor resistance in non-small cell lung cancer","volume":"15","author":"Xu","year":"2025","journal-title":"Front Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1568812","article-title":"Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors","volume":"8","author":"Elkrief","year":"2019","journal-title":"Oncoimmunology"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.105018","article-title":"Nanotechnology \u2013 microbiota synergy in cancer immunotherapy","volume":"217","author":"Yang","year":"2026","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1907688\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:25:22Z","timestamp":1790951122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1907688\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":95,"alternative-id":["10.3389\/fimmu.2026.1907688"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1907688","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"article-number":"1907688"}}